1. Medtech Insight
  2. >>Archive

Life's Grossman starts VC adventure; CEO takes stock

 
• By Madeleine Armstrong

Following the completion of its $13.6bn takeover by Thermo Fisher Scientific, former Life Technologies executive Paul Grossman has joined venture capital firm Telegraph Hill Partners as a venture partner. Dr Grossman was head of global strategy and corporate development at Life, where he was responsible for the company’s corporate strategy, licensing, business development and acquisition activities. Meanwhile, former Life chairman and CEO Greg Lucier is taking some time out after running a public company for 11 years, he told Clinica’s sister publication Scrip. Mr Lucier was appointed CEO of Invitrogen in 2003, which merged with Applied Biosystems in 2008 to form Life. He will remain active as a board member at companies including NuVasive, RainTree Oncology Services, Carefusion and the Sanford-Burnham Medical Institute in San Diego. "In time, I will get back into being a CEO," he said.

Following the completion of its $13.6bn takeover by Thermo Fisher Scientific, former Life Technologies executive Paul Grossman has joined venture capital firm Telegraph Hill Partners as a venture partner. Dr Grossman was head of global strategy and corporate development at Life, where he was responsible for the company’s corporate strategy, licensing, business development and acquisition activities. Meanwhile, former Life chairman and CEO Greg Lucier is taking some time out after running a public company for 11 years, he told Clinica’s sister publication Scrip. Mr Lucier was appointed CEO of Invitrogen in 2003, which merged with Applied Biosystems in 2008 to form Life. He will remain active as a board member at companies including NuVasive, RainTree Oncology Services, Carefusion and the Sanford-Burnham Medical Institute in San Diego. "In time, I will get back into being a CEO," he said.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By Marion Webb

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.

Industry Execs Talk Tariff Turbulence During MD&M East

 
• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

Bone Surgery Startup Surgify Medical Raises $7.9m

 
• By Natasha Barrow

Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.